The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to evaluate the effect that weight loss has on the severity of psoriasis in obese subjects. Fifty obese (BMI equal to or greater than 30) patients with moderate to severe plaque psoriasis will be enrolled in a weight loss intervention program. The severity of their psoriasis will be reevaluated at month 3 and month 6 of the program to determine what effect weight loss has had on their psoriasis. Serum TNF-alpha will be measured at month 0 and month 6. The hypothesis that will be tested is that weight loss will lead to a significant improvement in the severity of psoriasis and a reduction in TNF-alpha levels.

Condition or disease	Intervention/treatment	Phase
Psoriasis; Obesity	Behavioral: Weight Loss	Not Applicable

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	0 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients
Study Start Date :	June 2010
Actual Primary Completion Date :	May 2013
Actual Study Completion Date :	May 2013

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Weight Loss; Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.	Behavioral: Weight Loss; Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Severity of psoriasis [ Time Frame: 6 months ]
   The Psoriasis Area Severity Index (PASI) is the most common validated psoriasis severity assessment tool used in clinical trials, and combines redness, thickness, and scaliness of skin lesions with the body surface area that is affected. Most clinical trials define moderate to severe psoriasis as a PASI score of greater than or equal to 10, or a total Body Surface Area (BSA) of greater than or equal to 10%.

Secondary Outcome Measures :

1. Serum TNF-alpha levels [ Time Frame: 6 months ]
   Changes in TNF-alpha levels will be correlated to weight loss. TNF-alpha levels assess inflammatory conditions.

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• >18 years of age
• A Body Mass Index (BMI) >/= 30
• Subject has plaque psoriasis
• A Psoriasis Area Severity Index (PASI) score >/= 10 or a total body surface area (BSA) affected by psoriasis >/= 10%
• Capable of reading, understanding, and signing a consent form
• Females of childbearing potential must have negative urine pregnancy test on Day 0, and agree to a medically effective method of birth control (as determined by the investigator)

Exclusion Criteria:

• Already participating in a study for weight loss or a study of other psoriasis treatments
• If they are on systemic therapy for their psoriasis
• Female subjects who are pregnant or planning to become pregnant
• Patients with a history of anorexia nervosa, bulimia, or other diseases that would make a weight loss program a risk to their health
• Subjects unable to comply with study protocol

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Texas
University of Texas Dermatology Clinical Research
Houston, Texas, United States, 77030

Sponsors and Collaborators

The University of Texas Health Science Center, Houston

National Institutes of Health (NIH)

Investigators

Principal Investigator:	Adelaide Hebert, MD	University of Texas Medical School - Houston

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Adelaide Hebert, Professor, Director - Pediatric Dermatology, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:	NCT01137448 History of Changes
Other Study ID Numbers:	5T35DK007676-18 ( U.S. NIH Grant/Contract )
First Posted:	June 4, 2010
Last Update Posted:	December 16, 2013
Last Verified:	December 2013

Keywords provided by Adelaide Hebert, The University of Texas Health Science Center, Houston:

Psoriasis; Obesity

Additional relevant MeSH terms:

Psoriasis; Weight Loss; Skin Diseases, Papulosquamous; Skin Diseases	Body Weight Changes; Body Weight; Signs and Symptoms